Elvinix Secures Exclusive License to Advance Novel Peptide Therapy Aimed at Restoring Insulin Production in Type 1 Diabetes

Go back to Elvinix Secures Exclusive License to Advance Novel Peptide Therapy Aimed at Restoring Insulin Production in Type 1 Diabetes
(NASDAQ: ZEAL) Delayed: 17.59 --0 (-0%)
Previous Close $17.59    52 Week High $ 
Open $1.35    52 Week Low $ 
Day High $17.59    P/E N/A 
Day Low $17.59    EPS $ 
Volume 15,962